Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

被引：8

作者：

Kittai, Adam S. ^{[1
,4
]}

Best, Scott ^{[1
]}

Thurlow, Bria ^{[1
]}

Lam, Vi ^{[1
]}

Hashiguchi, Taylor ^{[1
]}

Goodyear, Shaun ^{[1
]}

Persky, Daniel O. ^{[2
]}

Okada, Craig ^{[1
]}

Park, Byung ^{[1
]}

Spurgeon, Stephen E. ^{[1
]}

Danilov, Alexey V. ^{[1
,3
]}

机构：

[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA

[2] Univ Arizona, Ctr Canc, Tucson, AZ USA

[3] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA

[4] Ohio State Univ, Columbus, OH 43210 USA

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 07期

关键词：

INHIBITION; SYK; IBRUTINIB; GS-9973; MCL-1;

D O I：

10.3324/haematol.2020.270298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In recent years, the utilization of CS-MWCNT as targeted drug carriers has attracted considerable attention. Hericium erinaceus polysaccharide (HEP) has been reported as an immunostimulant to improve immune responses. This study was focussed on developing CS-MWCNT encapsulating HEP (CS-MWCNT-HEP). Using in mice peritoneal macrophages, we found the immune response could be effectively regulated by CS-MWCNT-HEP, promoted the expression of the MHCII, CD86, F4/80 and gp38. Moreover, the mice immunized with CS-MWCNT-HEP nanoparticles significantly extended PCV2-specific IgG immune response and the levels of cytokines. The results demonstrated that CS-MWCNT-HEP may be a promising drug delivery system for immuno-enhancement. (c) 2021 Elsevier B.V. All rights reserved.

引用

页码：2022 / 2025

页数：4

共 15 条

[1] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study [J].

Awan, Farrukh T. ;

Thirman, Michael J. ;

Patel-Donnelly, Dipti ;

Assouline, Sarit ;

Rao, Arati, V ;

Ye, Wei ;

Hill, Brian ;

Sharman, Jeff P. .

LEUKEMIA & LYMPHOMA, 2019, 60 (08) :1972-1977

[2] Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials [J].

Bussel, James ;

Arnold, Donald M. ;

Grossbard, Elliot ;

Mayer, Jiri ;

Trelinski, Jacek ;

Homenda, Wojciech ;

Hellmann, Andrzej ;

Windyga, Jerzy ;

Sivcheva, Liliya ;

Khalafallah, Alhossain A. ;

Zaja, Francesco ;

Cooper, Nichola ;

Markovtsov, Vadim ;

Zayed, Hany ;

Duliege, Anne-Marie .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) :921-930

[3] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[4] Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase [J].

Currie, Kevin S. ;

Kropf, Jeffrey E. ;

Lee, Tony ;

Blomgren, Peter ;

Xu, Jianjun ;

Zhao, Zhongdong ;

Gallion, Steve ;

Whitney, J. Andrew ;

Maclin, Deborah ;

Lansdon, Eric B. ;

Maciejewski, Patricia ;

Rossi, Ann Marie ;

Rong, Hong ;

Macaluso, Jennifer ;

Barbosa, James ;

Di Paolo, Julie A. ;

Mitchell, Scott A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (09) :3856-3873

[5] Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies [J].

Danilov, Alexey V. ;

Persky, Daniel O. .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (01) :15-25

[6] Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia [J].

Danilov, Alexey V. ;

Herbaux, Charles ;

Walter, Harriet S. ;

Hillmen, Peter ;

Rule, Simon A. ;

Kio, Ebenezer A. ;

Karlin, Lionel ;

Dyer, Martin J. S. ;

Mitra, Siddhartha S. ;

Yi, Ping Cheng ;

Humeniuk, Rita ;

Huang, Xi ;

Zhou, Ziqian ;

Bhargava, Pankaj ;

Jurgensmeier, Juliane M. ;

Fegan, Christopher D. .

CLINICAL CANCER RESEARCH, 2020, 26 (12) :2810-2818

[7] Cell Death Pathways in Lymphoid Malignancies [J].

Fletcher, Luke ;

Nabrinsky, Edward ;

Liu, Tingting ;

Danilov, Alexey .

CURRENT ONCOLOGY REPORTS, 2020, 22 (01)

[8] Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia [J].

Friedberg, Jonathan W. ;

Sharman, Jeff ;

Sweetenham, John ;

Johnston, Patrick B. ;

Vose, Julie M. ;

LaCasce, Ann ;

Schaefer-Cutillo, Julia ;

De Vos, Sven ;

Sinha, Rajni ;

Leonard, John P. ;

Cripe, Larry D. ;

Gregory, Stephanie A. ;

Sterba, Michael P. ;

Lowe, Ann M. ;

Levy, Ronald ;

Shipp, Margaret A. .

BLOOD, 2010, 115 (13) :2578-2585

[9] Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells [J].

Gobessi, S. ;

Laurenti, L. ;

Longo, P. G. ;

Carsetti, L. ;

Berno, V. ;

Sica, S. ;

Leone, G. ;

Efremov, D. G. .

LEUKEMIA, 2009, 23 (04) :686-697

[10] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

← 1 2 →